QuidelOrtho and Allo Hope Foundation partner to advance prenatal care for maternal alloimmunization
Collaboration focuses on education, early testing, and improved access to care for patients at risk of HDFN
8 Jun 2026Industry news
QuidelOrtho and the Allo Hope Foundation, a nonprofit dedicated to supporting families and clinicians managing maternal alloimmunization, have announced a new collaboration focused on improving prenatal care through education, early testing, and stronger connections between laboratory providers, clinicians, and patients.
The partnership aims to address the serious risks maternal red blood cell alloimmunization poses to unborn and newborn children and to close information and care gaps that particularly affect underserved populations.
Maternal red blood cell alloimmunization is a serious, often misunderstood condition that can pose significant risks to the child during pregnancy. Red cell antibodies can cross the placenta and destroy fetal and neonatal red blood cells, causing hemolytic disease of the fetus and newborn (HDFN), a temporary but life-threatening condition that requires timely, specialized treatment.
Many families struggle to find clear, early, and actionable information about alloimmunization and HDFN, creating gaps in care that disproportionately affect underserved communities. The collaboration between QuidelOrtho and the Allo Hope Foundation is designed to change this by improving access to accurate information and promoting early, informed prenatal testing.
Shared purpose to improve maternal and fetal health outcomes
Rooted in a shared purpose, QuidelOrtho and Allo Hope will jointly develop resources that elevate patient voices, increase awareness among healthcare providers, and help ensure women receive informed, equitable prenatal testing and care from the very beginning of pregnancy.
Bryan Hanson, Executive Vice President, Global Portfolio Management and Marketing, QuidelOrtho, said, “Through this collaboration with the Allo Hope Foundation, we are activating that mission in a meaningful new way, helping ensure alloimmunized patients receive the early testing, accurate information and compassionate support they deserve. This is the perfect moment to highlight how diagnostics can directly improve maternal health outcomes, especially for those who have historically been underserved.”
Educational resources for laboratories, clinicians, and families
Beginning this summer, QuidelOrtho and the Allo Hope Foundation will release a series of co-produced educational materials designed for both lab technicians and families. These resources will focus on maternal red blood cell alloimmunization, HDFN, and the importance of early, equitable prenatal testing and care.
These educational assets will be made available through both organizations’ digital channels, supporting healthcare providers, laboratory professionals, and families seeking reliable information on alloimmunization and HDFN.
Bethany Weathersby, Founder and Executive Director, Allo Hope Foundation, said, “Families facing alloimmunization often feel overwhelmed and isolated. By collaborating with QuidelOrtho, we’re able to bring together clinical expertise, trusted diagnostics and lived experience to provide education that is both accurate and deeply human. We’re excited to broaden awareness and reach more families earlier, with clarity, compassion, and the support needed, to make survival the standard for children with HDFN.”
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Frequently asked questions
How are QuidelOrtho and the Allo Hope Foundation collaborating to improve prenatal care for maternal red blood cell alloimmunization and HDFN?
QuidelOrtho and the Allo Hope Foundation have launched a collaboration to improve prenatal care. Their partnership centers on education, early testing, and stronger connections between laboratory providers, clinicians, and patients. By jointly developing educational resources and promoting early, informed prenatal testing, they aim to address the serious risks that maternal red blood cell alloimmunization and hemolytic disease of the fetus and newborn (HDFN) pose, particularly in underserved populations.
What risks does maternal red blood cell alloimmunization pose to unborn and newborn children, and how does this collaboration aim to address them?
Maternal red blood cell alloimmunization is a serious condition in which red cell antibodies cross the placenta and destroy fetal and neonatal red blood cells. This can cause hemolytic disease of the fetus and newborn (HDFN), a temporary but life-threatening condition that requires timely, specialized treatment.
Many families struggle to find clear, early, and actionable information about alloimmunization and HDFN, leading to care gaps that disproportionately affect underserved communities. The collaboration between QuidelOrtho and the Allo Hope Foundation seeks to close these gaps by improving access to accurate information, elevating patient voices, and promoting early, equitable prenatal testing and care.
What educational resources will QuidelOrtho and the Allo Hope Foundation provide for laboratories, clinicians, and families dealing with alloimmunization and HDFN?
Beginning this summer, QuidelOrtho and the Allo Hope Foundation will release co-produced educational materials focused on maternal red blood cell alloimmunization, HDFN, and the importance of early, equitable prenatal testing and care. These resources are designed for both laboratory technicians and families, reinforcing a patient-centered approach that incorporates clinical expertise, trusted diagnostics, and lived experience.
The educational assets will be distributed through both organizations’ digital channels to support healthcare providers, laboratory professionals, and families seeking reliable information on alloimmunization and HDFN.